Loading
沛爾生醫-創 Stock: price and insider trades · Taiwan
TW·Mcap NT$51B
沛爾生醫-創: what insiders have been doing
This page follows insider dealings at 沛爾生醫-創 as filed with TWSE / TPEx (MOPS). Over the twelve months to 18 October 2026, 2 filings were filed, from 1 insider.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
No insider has bought 沛爾生醫-創 shares on the open market in the past twelve months.
Across the 523 companies tracked on its exchange, the median is 2 filings; at 2 filings, this issuer sits right on that mark.
Every figure here comes from the filings published by TWSE / TPEx (MOPS) and describes the past, not future prices; it is not investment advice.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 21,874 of 23,476 companies
18.4
score / 100
Value31
Quality6
FCF yld-1.0%
Earn yld-0.8%
EV/EBITDA·
ROE-24%
Gross mgn-14%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NT$39
Analyst consensus
Income statement
RevenueNT$31.4M
Gross profit-NT$4.4M-14% margin
EBITDA-NT$403.5M-1284% margin
Net income-NT$423.9M-1349.1% margin
Valuation
P/Book19.8x
Beta1.33
Balance sheet & cash
Market capNT$51B
Total debtNT$237.4M
Free Cash Flow-NT$508.9M
Debt / Equity8%
Profitability & ownership
ROE-24.2%
ROA-12.9%
% insiders0.0%
% institutions1.3%
Last declaration on 22 June 2026
About 沛爾生醫-創
Peir Biomedical-Innovation is a company listed on the XTAI market, specializing in the biotechnology sector. It focuses on developing innovative solutions for the healthcare industry.